STELABEC Supplementary data
Published: 24 November 2021| Version 2 | DOI: 10.17632/6bxhw3hxmf.2
Contributor:
Jonathan LondonDescription
Supplementary data for the investigator-initiated, prospective, open label , phase 2 STELABEC trial (NCT02648581) evaluating the efficacy and safety of ustekinumab for the treatment of recurrent oral ulcers resistant to colchicine in patients with Behçet disease
Files
Institutions
Assistance Publique - Hopitaux de Paris, Universite de Paris
Categories
Behcet's Syndrome